Company research
Apnimed, Inc.
CIK 1745648Updated Nov 6, 2026
SecurityAPMD · NASDAQ · equity
APMD price & chart
Loading TradingView…
NASDAQ:APMD on TradingView ↗About the company
We are a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases. Our sole clinical product candidate, AD109 (Oxnimbi), is an investigational, fixed-dose, anti-apneic neuromuscular modulator, combining a novel anti-muscarinic and a selective norepinephrine reuptake inhibitor (NRI) for the treatment of obstructive sleep apnea (OSA). Oxnimbi is designed to target the neuromuscular defect of OSA by improving upper airway muscle activity to help maintain airway patency and prevent airway collapse during sleep. Based on results from two registrational trials, we submitted a New Drug Application (NDA) for Oxnimbi to the U.S. Food and Drug Administration (FDA) in April 2026, which was accepted for review by the FDA in July 2026. The registrational trials were Phase 3, randomized, double-blind, placebo-controlled, parallel-arm trials in adults with mild to severe OSA, LunAIRo and SynAIRgy, which together enrolled approximately 1,300 patients and represent one of the largest and most diverse cohorts ever studied in an OSA pharmacologic trial. LunAIRo was…
In the news
Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update ↗
Seeking Alpha
Apnimed: Top Pick Biotech, Treating OSA With A Pill, Initiating With A Buy ↗
Apnimed: What We Know Heading Into The Feb PDUFA ↗
Apnimed, Inc. reports Q2 results ↗
SEC disclosures
Apnimed, Inc. files 8-K: Material Event ↗
Recent filings
Offerings
Registration 333-297377
- Gross proceeds
- 192000000.0
- Net proceeds
- 178560000.0
- Deal price
- 16.0
- Shares
- 12000000
- Offering price
- $16.00
- Ticker
- APMD
Underwriters: BofA Securities, Inc., Evercore Group L.L.C.
Registration 333-297849
Filing attachments
apmd-ex99_1.htm · S-8 · 2026-09-08
APNIMED, INC. 2026 INDUCEMENT PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Apnimed, Inc. 2026 Inducement Plan (as amended from time to time, the “Plan”). The purpose of the Plan is to enable Apnimed, Inc. (the “Company”) and its Affiliates to induce highly-qualified prospective officers and employees who are Eligible Employees to accept employment and to provide them with a proprietary interest in the Company. It is anticipated that providing such pers…
Read attachment ↗apmd-ex99_2.htm · S-8 · 2026-09-08
NON-QUALIFIED STOCK OPTION AGREEMENT UNDER THE APNIMED, INC. 2026 INDUCEMENT PLAN Name of Optionee: No. of Option Shares: Option Exercise Price per Share: $ Grant Date: Expiration Date: Pursuant to the Apnimed, Inc. 2026 Inducement Plan as amended through the date hereof (the “Plan”), Apnimed, Inc. (the “Company”) hereby grants to the Optionee named above an option (the “Stock Option”) to purchase on or prior to the Expiration Date specified above all or part of the number of shares of Co…
Read attachment ↗apmd-ex99_1.htm · 8-K · 2026-09-08
EX-99.1 2 apmd-ex99_1.htm EX-99.1 EX-99.1 EX-99.1 Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update • U.S. Food and Drug Administration (“FDA”) Accepted the NDA for AD109, with a proposed proprietary name Oxnimbi™, and assigned a PDUFA target action date of February 28, 2027 • If approved, Oxnimbi has the potential to become the first oral pharmacologic therapy designed to address the neuromuscular root cause of upper airway collapse for the millions of …
Read attachment ↗apni-ex4_1.htm · S-1/A · 2026-07-27
Exhibit 4.1 The following abbreviations, when used in the inscription on the face of this certificate, shall be construed as though they were written out in full according to applicable laws or regulations: TEN COM as tenants in common UNIF GIFT MIN ACT –– ..................Custodian .................. TEN ENT as te…
Read attachment ↗apni-ex4_2.htm · S-1 · 2026-07-10
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES OR “BLUE SKY LAWS,” AND MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APP…
Read attachment ↗apni-ex4_3.htm · S-1 · 2026-07-10
Exhibit 4.3 APNIMED, INC. SIXTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT TABLE OF CONTENTS Page 1. Definitions 1 2. Registration Rights 4 2.1 Demand Registration …
Read attachment ↗